– USA, TX – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced the election of Ivan Cheung to its Board of Directors. His appointment is concurrent with the retirement of Dr. Bob Lefkowitz from the Board after 23 years of service.
About Ivan H. Cheung
Ivan Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is CEO and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023.
“I am honored to join the Lexicon Board of Directors at this pivotal moment in the company’s history, and to support its mission of pioneering medicines that transform patients’ lives,” said Ivan Cheung. “The breakthrough potential in Lexicon’s commercial and R&D pipeline is inspiring, as is the dedication and culture of the team.”
Ivan Cheung served in a series of executive leadership positions at Eisai Co., Ltd., over 18 years, most recently as chairman and CEO of Eisai Inc. from 2016 to July 2023 and strategic advisor from August to December 2023. Before joining Eisai, he spent seven years with Booz Allen Hamilton, Inc., where he held a variety of consulting positions.
Ivan Cheung holds a B.S.E from Duke University and an M.B.A. from Harvard University.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000 program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has commercially launched one of these medicines, INPEFA (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism, and other indications.
For more: https://www.lexpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.